Third-party preclinical safety studies confirmed the product to be safe and well tolerated.

Preclinical data supports that IMM01-STEM (formerly IMMUNA) benefits vascular function, tissue inflammation, immune cell function, and exosome/extracellular vesicle composition in several age and immune-associated disease indications. Immunis is in the process of publishing preclinical data showing that IMM01-STEM benefits metabolism.

In published, non-clinical mouse studies in aged mice and in a model of muscle atrophy, IMM01-STEM was shown to increase muscle mass, increase muscle strength and diminish skeletal muscle fibrosis. These results demonstrate the efficacy of IMM01-STEM in attenuating loss of muscle mass and muscle fiber area during disuse atrophy in aged mice. We invite you to learn more about these results published in GeroScience.